Heron Therapeutics
Heron Therapeutics is dedicated to improving patients' lives by developing best-in-class medicines that address unmet medical needs. They focus on innovative science and technologies to create therapies that elevate the standard of care in oncology and acute care, aiming to bring new medicines to patients and healthcare providers quickly. The company fosters an entrepreneurial culture emphasizing core values such as putting patients first, doing the right thing, transparent communication, results-driven accountability, and respectful collaboration. Heron offers comprehensive benefits, modern amenities at its San Diego headquarters, and opportunities for professional growth. The company actively recruits passionate individuals committed to making a difference in healthcare.
Industries
Nr. of Employees
medium (51-250)
Heron Therapeutics
4242 Campus Point Court, Suite 200, San Diego, CA 92121
Patents
Products
SUSTOL®
An extended-release injection approved by the FDA for the prevention of nausea and vomiting associated with chemotherapy.
CINVANTI®
An injectable emulsion approved by the FDA for the prevention of nausea and vomiting related to chemotherapy, available as a 2-minute IV push or 30-minute infusion.
ZYNRELEF®
A dual-acting local anesthetic approved in multiple countries for postoperative pain management.
APONVIE™
An FDA-approved IV injection for postoperative nausea and vomiting.
SUSTOL®
An extended-release injection approved by the FDA for the prevention of nausea and vomiting associated with chemotherapy.
CINVANTI®
An injectable emulsion approved by the FDA for the prevention of nausea and vomiting related to chemotherapy, available as a 2-minute IV push or 30-minute infusion.
ZYNRELEF®
A dual-acting local anesthetic approved in multiple countries for postoperative pain management.
APONVIE™
An FDA-approved IV injection for postoperative nausea and vomiting.
Services
Heron applies innovative science and technologies to provide better ways to reduce postoperative pain and prevent postoperative nausea and vomiting.
Heron is focused on elevating the standard of care for oncology patients by developing solutions that help manage and reduce the negative side effects of cancer treatments.
Heron applies innovative science and technologies to provide better ways to reduce postoperative pain and prevent postoperative nausea and vomiting.
Heron is focused on elevating the standard of care for oncology patients by developing solutions that help manage and reduce the negative side effects of cancer treatments.
News & Updates
Heron announced its first quarter 2025 financial results and recent corporate updates.
Heron announced a settlement related to patent litigations for CINVANTI® and APONVIE®.
Heron announced the appointment of Mark Hensley as Chief Operating Officer.
Heron announced its first quarter 2025 financial results and recent corporate updates.
Heron announced a settlement related to patent litigations for CINVANTI® and APONVIE®.
Heron announced the appointment of Mark Hensley as Chief Operating Officer.